330 related articles for article (PubMed ID: 31906826)
1. Dexamethasone enhances the antitumor efficacy of Gemcitabine by glucocorticoid receptor signaling.
Gong JH; Zheng YB; Zhang MR; Wang YX; Yang SQ; Wang RH; Miao QF; Liu XJ; Zhen YS
Cancer Biol Ther; 2020 Apr; 21(4):332-343. PubMed ID: 31906826
[TBL] [Abstract][Full Text] [Related]
2. Gemcitabine potentiates anti-tumor effect of resveratrol on pancreatic cancer via down-regulation of VEGF-B.
Yang Y; Tian W; Yang L; Zhang Q; Zhu M; Liu Y; Li J; Yang L; Liu J; Shen Y; Qi Z
J Cancer Res Clin Oncol; 2021 Jan; 147(1):93-103. PubMed ID: 32897433
[TBL] [Abstract][Full Text] [Related]
3. Quercetin induces apoptosis and enhances gemcitabine therapeutic efficacy against gemcitabine-resistant cancer cells.
Liu ZJ; Xu W; Han J; Liu QY; Gao LF; Wang XH; Li XL
Anticancer Drugs; 2020 Aug; 31(7):684-692. PubMed ID: 32282368
[TBL] [Abstract][Full Text] [Related]
4. Combined effect of dehydroxymethylepoxyquinomicin and gemcitabine in a mouse model of liver metastasis of pancreatic cancer.
Suzuki K; Aiura K; Matsuda S; Itano O; Takeuchi O; Umezawa K; Kitagawa Y
Clin Exp Metastasis; 2013 Apr; 30(4):381-92. PubMed ID: 23111540
[TBL] [Abstract][Full Text] [Related]
5. New treatment strategy with nuclear factor-κB inhibitor for pancreatic cancer.
Horiuchi T; Uwagawa T; Shirai Y; Saito N; Iwase R; Haruki K; Shiba H; Ohashi T; Yanaga K
J Surg Res; 2016 Nov; 206(1):1-8. PubMed ID: 27916347
[TBL] [Abstract][Full Text] [Related]
6. Enhanced antitumor efficacy by the combination of emodin and gemcitabine against human pancreatic cancer cells via downregulation of the expression of XIAP in vitro and in vivo.
Wang ZH; Chen H; Guo HC; Tong HF; Liu JX; Wei WT; Tan W; Ni ZL; Liu HB; Lin SZ
Int J Oncol; 2011 Nov; 39(5):1123-31. PubMed ID: 21743963
[TBL] [Abstract][Full Text] [Related]
7. Imexon enhances gemcitabine cytotoxicity by inhibition of ribonucleotide reductase.
Roman NO; Samulitis BK; Wisner L; Landowski TH; Dorr RT
Cancer Chemother Pharmacol; 2011 Jan; 67(1):183-92. PubMed ID: 20339847
[TBL] [Abstract][Full Text] [Related]
8. HS-104, a PI3K inhibitor, enhances the anticancer efficacy of gemcitabine in pancreatic cancer.
Jung KH; Yan HH; Fang Z; Son MK; Lee H; Hong S; Hong SS
Int J Oncol; 2014 Jul; 45(1):311-21. PubMed ID: 24819705
[TBL] [Abstract][Full Text] [Related]
9. Maslinic acid potentiates the antitumor activities of gemcitabine in vitro and in vivo by inhibiting NF-κB-mediated survival signaling pathways in human gallbladder cancer cells.
Yu Y; Wang J; Xia N; Li B; Jiang X
Oncol Rep; 2015 Apr; 33(4):1683-90. PubMed ID: 25633045
[TBL] [Abstract][Full Text] [Related]
10. Escin augments the efficacy of gemcitabine through down-regulation of nuclear factor-κB and nuclear factor-κB-regulated gene products in pancreatic cancer both in vitro and in vivo.
Wang YW; Wang SJ; Zhou YN; Pan SH; Sun B
J Cancer Res Clin Oncol; 2012 May; 138(5):785-97. PubMed ID: 22270965
[TBL] [Abstract][Full Text] [Related]
11. S-Adenosylmethionine synergistically enhances the antitumor effect of gemcitabine against pancreatic cancer through JAK2/STAT3 pathway.
Liu Y; Bi T; Liu L; Gao Q; Shen G; Qin L
Naunyn Schmiedebergs Arch Pharmacol; 2019 May; 392(5):615-622. PubMed ID: 30683944
[TBL] [Abstract][Full Text] [Related]
12. Gemcitabine/cannabinoid combination triggers autophagy in pancreatic cancer cells through a ROS-mediated mechanism.
Donadelli M; Dando I; Zaniboni T; Costanzo C; Dalla Pozza E; Scupoli MT; Scarpa A; Zappavigna S; Marra M; Abbruzzese A; Bifulco M; Caraglia M; Palmieri M
Cell Death Dis; 2011 Apr; 2(4):e152. PubMed ID: 21525939
[TBL] [Abstract][Full Text] [Related]
13. The combination of gemcitabine plus an anti-FGFR inhibitor can have a synergistic antitumor effect on FGF-activating cholangiocarcinoma.
Ito Y; Yamada D; Kobayashi S; Sasaki K; Iwagami Y; Tomimaru Y; Asaoka T; Noda T; Takahashi H; Shimizu J; Doki Y; Eguchi H
Cancer Lett; 2024 Jul; 595():216997. PubMed ID: 38801887
[TBL] [Abstract][Full Text] [Related]
14. Mechanisms of metformin's anti‑tumor activity against gemcitabine‑resistant pancreatic adenocarcinoma.
Suzuki K; Takeuchi O; Suzuki Y; Kitagawa Y
Int J Oncol; 2019 Feb; 54(2):764-772. PubMed ID: 30570108
[TBL] [Abstract][Full Text] [Related]
15. Pretreatment with S-1, an oral derivative of 5-fluorouracil, enhances gemcitabine effects in pancreatic cancer xenografts.
Nakahira S; Nakamori S; Tsujie M; Takeda S; Sugimoto K; Takahashi Y; Okami J; Marubashi S; Miyamoto A; Takeda Y; Nagano H; Dono K; Umeshita K; Sakon M; Monden M
Anticancer Res; 2008; 28(1A):179-86. PubMed ID: 18383843
[TBL] [Abstract][Full Text] [Related]
16. Emodin potentiates the antitumor effects of gemcitabine in PANC-1 pancreatic cancer xenograft model in vivo via inhibition of inhibitors of apoptosis.
Guo HC; Bu HQ; Luo J; Wei WT; Liu DL; Chen H; Tong HF; Wang ZH; Wu HY; Li HH; Zuo MM; Li W; Lin SZ
Int J Oncol; 2012 Jun; 40(6):1849-57. PubMed ID: 22378302
[TBL] [Abstract][Full Text] [Related]
17. Synergistic antitumor activity of ZD6474, an inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling, with gemcitabine and ionizing radiation against pancreatic cancer.
Bianco C; Giovannetti E; Ciardiello F; Mey V; Nannizzi S; Tortora G; Troiani T; Pasqualetti F; Eckhardt G; de Liguoro M; Ricciardi S; Del Tacca M; Raben D; Cionini L; Danesi R
Clin Cancer Res; 2006 Dec; 12(23):7099-107. PubMed ID: 17145834
[TBL] [Abstract][Full Text] [Related]
18. Notch signaling pathway targeted therapy suppresses tumor progression and metastatic spread in pancreatic cancer.
Yabuuchi S; Pai SG; Campbell NR; de Wilde RF; De Oliveira E; Korangath P; Streppel MM; Rasheed ZA; Hidalgo M; Maitra A; Rajeshkumar NV
Cancer Lett; 2013 Jul; 335(1):41-51. PubMed ID: 23402814
[TBL] [Abstract][Full Text] [Related]
19. Dual inhibition of the PI3K and MAPK pathways enhances nab-paclitaxel/gemcitabine chemotherapy response in preclinical models of pancreatic cancer.
Awasthi N; Kronenberger D; Stefaniak A; Hassan MS; von Holzen U; Schwarz MA; Schwarz RE
Cancer Lett; 2019 Sep; 459():41-49. PubMed ID: 31153980
[TBL] [Abstract][Full Text] [Related]
20.
Yang H; Tong Z; Shen L; Sun YU; Hoffman RM; Huang J
Anticancer Res; 2020 Sep; 40(9):4969-4978. PubMed ID: 32878785
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
